Drugs / Cabazitaxel
Cabazitaxel
also known as
XRP6258 · Jevtana · Cabazitaxel accord · Cabazitaxel acetonate · JEVTANA (cabazitaxel) · Jevtana kit · NSC-761432 · RPR116258 · +1 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | JEVTANA KIT | — | 2017-05-17 – 2020-12-18 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Cabazitaxel Teva | — | 2019-07-11 | europa.eu ↗ |
| Approved | EU (EMA) | Jevtana | — | 2011-03-17 | europa.eu ↗ |
| Approved | US (FDA) | JEVTANA KIT | — | 2010-06-17 | fda.gov ↗ |
Trials 102 · started per year
today
US approved 2010
EU approved 2011
1
1
2
3
10
20
16
11
10
2
7
4
2
3
3
1
2
1
3
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03110588 | May 2018 → Dec 2019 | metastatic prostate carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT01594918 | Jun 2012 → Aug 2016 | prostate carcinoma | Rahul Aggarwal | Completed | No outcome recorded |
| Phase 1 | NCT01527929 | Apr 2012 → Nov 2013 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01447225 | Oct 2011 → Nov 2013 | cancer | Merrimack Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01420250 | Sep 2011 → Jul 2015 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT01379339 | Apr 2011 → Jan 2015 | head and neck squamous cell carcinoma | Krzysztof Misiukiewicz | Completed | No outcome recorded |
| Phase 1 | NCT01324583 | Jan 2011 → Nov 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01140607 | May 2010 → Jul 2014 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01087021 | Mar 2010 → Apr 2011 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00925743 | Jun 2009 → Mar 2013 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01755390 | Oct 1999 → Aug 2002 | neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01981668 | ? → Sep 2013 | prostate neoplasm | Nova Scotia Cancer Centre | Withdrawn | No outcome recorded |
| Phase 1/211 trials · 1 met primary | ||||||
| Phase 1/2 | NCT06353386 | May 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05340374 | Jul 2022 → Jun 2026 overdue | castration-resistant prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02522715 | Aug 2015 → Oct 2019 overdue | castration-resistant prostate carcinoma, metastatic prostate carcinoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02202772 | Dec 2014 → Apr 2026 overdue | urothelial carcinoma | Guarionex J. Decastro | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01740570 | Apr 2013 → Apr 2017 | brain cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01751308 | Feb 2013 → Jul 2015 | nervous system cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01505868 | Jul 2012 → Dec 2019 | castration-resistant prostate carcinoma, lymph node disorder, metastatic carcinoma in the bone, metastatic prostate carcinoma +2 | M.D. Anderson Cancer Center | Completed | Met primary |
| Phase 1/2 | NCT01511536 | Mar 2012 → Jul 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01497964 | Dec 2011 → May 2013 | gastric cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01335204 | Jun 2011 → Mar 2013 | prostate cancer | Medical University of South Carolina | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01001221 | Nov 2009 → Oct 2011 | cancer | Sanofi | Terminated | No outcome recorded |
| Phase 261 trials · 2 met primary · 3 missed | ||||||
| Phase 2 | NCT06738303 | Jul 2025 → Feb 2028 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06890832 | May 2025 → Dec 2026 expected | castration-resistant prostate carcinoma | Jina Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06632977 | Feb 2025 → Apr 2030 expected | castration-resistant prostate carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT05563558 | May 2023 → Nov 2026 expected | metastatic prostate carcinoma | Fundacion Oncosur | Recruiting | No outcome recorded |
| Phase 2 | NCT05005728 | Oct 2021 → Jun 2025 | castration-resistant prostate carcinoma | Xencor, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04709276 | Jun 2021 → Feb 2026 overdue | metastatic prostate carcinoma, prostate neuroendocrine neoplasm | Andrew J. Armstrong, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04622761 | Jan 2021 → Nov 2025 | prostate cancer | The Clatterbridge Cancer Centre NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT04592237 | Dec 2020 → Dec 2027 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate small cell carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04495179 | Aug 2020 → Nov 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03934840 | Oct 2019 → Jun 2023 | prostate cancer | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT03764540 | Apr 2019 → Dec 2024 | metastatic prostate carcinoma | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 2 | NCT03101046 | Nov 2018 → Dec 2021 | castration-resistant prostate carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT03419234 | Apr 2018 → Jan 2024 overdue | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | Met primary |
| Phase 2 | NCT03257891 | Jan 2018 → Jan 2021 | adrenal cortex carcinoma | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Unknown | No outcome recorded |
| Phase 2 | NCT02844582 | Dec 2017 → Jun 2019 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | University of California, Davis | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03356912 | Nov 2017 → May 2021 | castration-resistant prostate carcinoma | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 2 | NCT03263650 | Oct 2017 → Jun 2026 | prostate cancer aggressiveness quantitative trait locus on chromosome 19, prostate carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02985957 | Mar 2017 → Apr 2022 | prostate cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT03050866 | Feb 2017 → Jan 2022 | metastatic prostate carcinoma | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02903160 | Jan 2017 → Nov 2021 | prostate cancer | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02543255 | Sep 2016 → May 2021 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT02621190 | Feb 2016 → Feb 2019 | prostate cancer | Erasmus Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02512458 | Oct 2015 → Dec 2019 | metastatic prostate carcinoma | Hellenic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT02560337 | Sep 2015 → Dec 2018 | ovarian cancer | Vejle Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02166658 | Aug 2015 → Apr 2017 | breast cancer, lung cancer, metastatic malignant neoplasm in the brain | AIO-Studien-gGmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02379390 | Jun 2015 → May 2018 | metastatic prostate carcinoma | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02478502 | Jun 2015 → Dec 2022 | testicular cancer | University Hospital, Akershus | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03114254 | Dec 2014 → Nov 2016 | penile carcinoma | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT03048942 | Nov 2014 → Aug 2025 | Her2-receptor negative breast cancer | University Hospitals Bristol and Weston NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT02254785 | Oct 2014 → May 2020 | castration-resistant prostate carcinoma | British Columbia Cancer Agency | Unknown | Met primary |
| Phase 2 | NCT01913652 | Oct 2014 → Dec 2020 | dedifferentiated liposarcoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT02218606 | Aug 2014 → Oct 2023 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02115165 | Jul 2014 → Apr 2022 | nongerminomatous germ cell tumor | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 2 | NCT01934894 | May 2014 → Feb 2016 | metastatic malignant neoplasm in the brain | SCRI Development Innovations, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02035124 | Apr 2014 → Jan 2015 | prostate cancer | SCRI Development Innovations, LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01866449 | Oct 2013 → Dec 2016 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT01913067 | Sep 2013 → May 2016 | breast cancer, metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Jules Bordet Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01956149 | Sep 2013 → Dec 2017 | gastric cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2 | NCT01845792 | Jul 2013 → Feb 2017 | prostate cancer | University of Colorado, Denver | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01941550 | Jul 2013 → Jan 2016 | neoplastic disease or syndrome | RWTH Aachen University | Terminated | No outcome recorded |
| Phase 2 | NCT01718353 | Mar 2013 → Aug 2015 | metastatic prostate carcinoma | Sanofi | Completed | Mixed |
| Phase 2 | NCT02204332 | Mar → Sep 2013 | colorectal cancer | Hospital Clinico Universitario de Santiago | Terminated | No outcome recorded |
| Phase 2 | NCT01779479 | Feb 2013 → Aug 2015 | breast cancer | GBG Forschungs GmbH | Completed | Missed primary |
| Phase 2 | NCT01750866 | Feb → Oct 2013 | prostate carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01650285 | Jan 2013 → Jul 2014 | prostate cancer | Brown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01747239 | Jan 2013 → Jul 2014 | ovarian cancer | Vejle Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01757171 | Dec 2012 → Jul 2016 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01852578 | Sep 2012 → Aug 2013 | non-small cell lung carcinoma | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 2 | NCT01693549 | Sep 2012 → Jul 2017 | breast cancer | Hellenic Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01576029 | Aug 2012 → Dec 2013 | prostate neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01616875 | Jul 2012 → Nov 2017 | infiltrating bladder urothelial carcinoma | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT01531205 | May 2012 → Sep 2013 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01518283 | May 2012 → Jun 2016 | hormone-resistant prostate carcinoma | Spanish Oncology Genito-Urinary Group | Completed | No outcome recorded |
| Phase 2 | NCT01600339 | May 2012 → Jan 2015 | urothelial carcinoma | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 2 | NCT01541007 | Apr 2012 → Oct 2015 | castration-resistant prostate carcinoma | Jeffrey Yachnin M.D., PhD. | Completed | No outcome recorded |
| Phase 2 | NCT01620242 | Apr 2012 → Jun 2013 | head and neck cancer | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT01500720 | Mar 2012 → Apr 2014 | small cell lung carcinoma | Sanofi | Completed | Missed primary |
| Phase 2 | NCT01437488 | Feb 2012 → Aug 2014 | urothelial carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT01528163 | Feb 2012 → Nov 2014 | head and neck squamous cell carcinoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | Missed primary |
| Phase 2 | NCT01558219 | Nov 2011 → Dec 2014 | metastatic prostate carcinoma | Tampere University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01365130 | Jun 2011 → Dec 2012 | esophageal disorder, gastric cancer, gastroesophageal cancer | Howard Safran | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT03258320 | Jan 2015 → Dec 2026 expected | prostate cancer | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01668459 | Jan 2013 → Nov 2017 | transitional cell carcinoma | Dr Anjali Zarkar | Completed | No outcome recorded |
| Phase 2/3 | NCT01830231 | Oct 2012 → Nov 2016 | urothelial carcinoma | Associació per a la Recerca Oncologica, Spain | Unknown | Missed primary |
| Phase 38 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT02961257 | May 2017 → Dec 2021 | metastatic prostate carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Completed | No outcome recorded |
| Phase 3 | NCT02044354 | May 2014 → Apr 2017 | prostate carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | Met primary |
| Phase 3 | NCT01952223 | Dec 2013 → Dec 2025 overdue | prostate adenocarcinoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01978873 | Nov 2012 → Nov 2018 | prostate cancer | Örebro University, Sweden | Unknown | No outcome recorded |
| Phase 3 | NCT01308567 | May 2011 → Sep 2015 | prostate cancer | Sanofi | Completed | Missed primary |
| Phase 3 | NCT01308580 | Apr 2011 → Aug 2015 | prostate cancer | Sanofi | Completed | Met primary |
| Phase 3 | NCT01254279 | Dec 2010 → Dec 2014 | metastatic prostate carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00417079 | Jan 2007 → Sep 2009 | prostate neoplasm | Sanofi | Completed | Met primary |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT02485691 | Nov 2015 → Mar 2019 | metastatic prostate carcinoma | Sanofi | Completed | Met primary |
| Phase 4 | NCT02441894 | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02074137 | Jul 2014 → Mar 2016 | metastatic prostate carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01649635 | Jul 2012 → Jan 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1 | NCT03043989 Comparator | Mar 2017 → Jul 2019 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06085729 Background | Feb 2024 → Sep 2027 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05762536 Background | Nov 2023 → May 2027 expected | prostate carcinoma | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03556904 Background | Dec 2018 → Jul 2023 | prostate cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03248570 Background | Feb 2018 → Sep 2023 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT03392428 Comparator | Jan 2018 → Dec 2019 | metastatic malignant neoplasm, prostate cancer | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT02703623 Comparator | May 2016 → Mar 2028 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01469338 Background | Jul 2012 → Oct 2014 | diarrheal disease, hormone-resistant prostate carcinoma | University of Southern California | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT07852195 Comparator | Jan 2027 → Mar 2029 expected | prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03295565 Comparator | May 2017 → Dec 2020 | metastatic neoplasm, metastatic prostate carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT07611110 Comparator | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07213674 Comparator | Nov 2025 → Jan 2030 expected | prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06855277 Comparator | Jul 2025 → Sep 2028 expected | prostate cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06691984 Comparator | Dec 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06470243 Background | Nov 2024 → Jun 2029 expected | castration-resistant prostate carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT03903835 Comparator | Feb 2019 → Dec 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Karolinska Institutet | Recruiting | Met primary |
| Phase 3 | NCT01578655 Background | Aug 2012 → Jul 2016 | prostate cancer | Achieve Life Sciences | Completed | Missed primary |
| Phase 3 | NCT01083615 Background | Mar 2010 → Mar 2013 | castration-resistant prostate carcinoma, hormone-resistant prostate carcinoma | Achieve Life Sciences | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2024-01-18 | Starpharma Pty Ltd | Results DEP cabazitaxel data presentation at ASCO GI cancer meeting starpharma.com ↗
DEP® cabazitaxel achieved disease control rates of 100% and 50%, respectively, in these advanced and typically hard-to-treat gastro-oesophageal cancers, which have a one-year survival rate of approximately 20%3,4. |
| 2023-11-14 | Starpharma Pty Ltd | Results Starpharma Presents at Bell Potter Conference starpharma.com ↗
75% of the evaluable ovarian cancer patients achieved reductions of up to 95% in ovarian cancer biomarkers, CA125, or CEA. |
| 2023-10-25 | Starpharma Pty Ltd | Results SPL to present DEP radiotheranostics at Wilsons Conference starpharma.com ↗
DEP® cabazitaxel achieved a disease control rate (DCR) of 66.7% and an objective response rate (ORR) of 17.6% |
| 2023-10-17 | Starpharma Pty Ltd | Results Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer starpharma.com ↗
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. |
| 2023-06-23 | Starpharma Pty Ltd | Results Life Sciences Investor Forum Presentation starpharma.com ↗ |
| 2022-11-10 | Xencor, Inc. | Results Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting xencor.com ↗
As of the data cut on September 7, 2022 , prostate-specific antigen (PSA) reductions of more than 50% from baseline (PSA50) had been observed in three of nine patients, inclusive of all cohorts and time on study. |
| 2022-09-15 | Starpharma Pty Ltd | Results Starpharma to present at Life Sciences Investor Forum starpharma.com ↗
the latest interim clinical trial results presented at ESMO oncology conference that show efficacy signals in 100% of prostate cancer patients assessed following DEP® cabazitaxel treatment; |
| 2022-09-11 | Starpharma Pty Ltd | Results New clinical data for DEP cabazitaxel in prostate cancer starpharma.com ↗ |
| 2022-07-25 | NATCO Pharma Ltd. | Regulatory NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (generic for Jevtana Kit®) natcopharma.co.in ↗
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces today that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®) for the 60mg/1.5mL (40mg/mL) strength. |
| 2021-11-25 | Starpharma Pty Ltd | Results Positive DEP phase 2 interim results in prostate cancer starpharma.com ↗
Starpharma reports positive interim results for the prostate cancer cohort in its phase 2 DEP® cabazitaxel clinical trial, all of whom have hormone refractory, Stage IV metastatic disease |
| 2020-01-29 | Starpharma Pty Ltd | Results Shareholder Update January 2020 starpharma.com ↗
In phase 1, e ncouraging efficacy signals were observed in 67% of patients assessed and included prolonged stable disease in multiple tumour types, including prostate cancer. |
| 2019-12-09 | Starpharma Pty Ltd | Results DEP cabazitaxel progresses to phase 2 on positive results starpharma.com ↗
The trial met its objective of evaluating safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose of 20 mg/m2. |
| 2019-08-27 | Starpharma Pty Ltd | Results Promising efficacy signals observed in ongoing DEP trials starpharma.com ↗
Efficacy signals for DEP® cabazitaxel include patients with stable disease of more than 30 weeks (treatment ongoing) and significant reductions in specific tumour biomarkers, such as Prostate Specific Antigen (PSA) |
| 2018-01-30 | Starpharma Pty Ltd | Regulatory Starpharma to commence DEP cabazitaxel phase 1/2 trial starpharma.com ↗ |
| 2016-05-24 | Starpharma Pty Ltd | Results Starpharma's DEP eliminates cabazitaxel neutropenia starpharma.com ↗
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana ®) in a preclinical study (see Figure 1). |
| 2016-04-04 | Starpharma Pty Ltd | Results Starpharma to present at Bio-Europe conference starpharma.com ↗ |
| 2016-04-03 | Starpharma Pty Ltd | Results DEP cabazitaxel shows complete, sustained tumour regression starpharma.com ↗ |
All press releases naming this drug 20 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 122 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cabazitaxel | “Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although other standard agents (e.g. docetaxel,...” NCT03556904 ↗117“Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin).” NCT03248570 ↗ “The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).” NCT06855277 ↗ “Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion” NCT01779479 ↗ “Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week” NCT01558219 ↗ “Busulfan Cabazitaxel Cabozantinib” NCT02551718 ↗ |
| Known as | Cabazitaxel accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201748 ↗ |
| Known as | Cabazitaxel acetonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201748 ↗ |
| Known as | Jevtana | “Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week” NCT01558219 ↗ |
| Known as | JEVTANA (cabazitaxel) | “JEVTANA® (cabazitaxel)” NCT01335204 ↗ |
| Known as | Jevtana kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201748 ↗ |
| Known as | NSC-761432 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201748 ↗ |
| Known as | RPR116258 | “cabazitaxel (XRP6258) (RPR116258)” NCT00417079 ↗ |
| Known as | TXD 258 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201748 ↗ |
| Known as | XRP6258 | “Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel” NCT01528163 ↗17“cabazitaxel (XRP6258) (RPR116258)” NCT00417079 ↗ “Drug: CABAZITAXEL (XRP6258)” NCT01649635 ↗ “Drug: Cabazitaxel (XRP6258)” NCT01324583 ↗ “Drug: CABAZITAXEL XRP6258” NCT02074137 ↗ “Cabazitaxel (XRP6258)” NCT01140607 ↗ “CABAZITAXEL (XRP6258)” NCT01718353 ↗ “Cabazitaxel (XRP6258)” NCT01308580 ↗ “Cabazitaxel (XRP6258)” NCT01751308 ↗ “Cabazitaxel (XRP6258)” NCT01755390 ↗ “Cabazitaxel (XRP6258)” NCT01308567 ↗ |
| Action | Inhibit | “thus inhibit mitosis” NCT05340374 ↗ |
| Modality | Other / unclassified | “Cabazitaxel is an agent in the taxane family designed to be active in the setting of acquired multi-drug resistance that arises in some tumors.” NCT01437488 ↗ |
| Route | Intravenous | “25 mg/m(2) cabazitaxel intravenously over 1 h every 3 weeks.” PMID 20888992 ↗ Oct 2010 |